Electromed (ELMD) 10-Q 14 May 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Mar. 31, 2014	9-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Electromed, Inc.	'
Entity Central Index Key	'0001488917	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	8,114,252

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Jun. 30, 2013
Current Assets	'	'
Cash and cash equivalents	$772,428	$503,564
Accounts receivable (net of allowances for doubtful accounts of $45,000)	6,469,927	9,014,043
Inventories	2,550,815	1,379,594
Prepaid expenses and other current assets	448,262	428,843
Income taxes receivable	529,599	538,285
Deferred income taxes, net	'	557,000
Total current assets	10,771,031	12,421,329
Property and equipment, net	3,972,254	3,743,675
Finite-life intangible assets, net net	993,807	1,080,734
Other assets	359,504	310,089
Total assets	16,096,596	17,555,827
Current Liabilities	'	'
Current maturities of long-term debt	45,758	57,540
Accounts payable	1,004,025	643,681
Accrued compensation	326,846	565,023
Warranty reserve	740,000	680,000
Other accrued liabilities	295,446	247,267
Total current liabilities	2,412,075	2,193,511
Long-term debt, less current maturities	1,262,889	1,332,455
Deferred income taxes, net	'	103,000
Total liabilities	3,674,964	3,628,966
Commitments and Contingencies (Note 7)	'	'
Equity	'	'
Common stock, $0.01 par value; authorized: 13,000,000; shares issued and outstanding: 8,114,252 shares	81,143	81,143
Additional paid-in capital	13,208,759	13,134,938
(Accumulated deficit) retained earnings	-868,270	710,780
Total equity	12,421,632	13,926,861
Total liabilities and equity	$16,096,596	$17,555,827

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Jun. 30, 2013
Condensed Consolidated Balance Sheets [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$45,000	$45,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	13,000,000	13,000,000
Common stock, shares issued	8,114,252	8,114,252
Common stock, shares outstanding	8,114,252	8,114,252

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Operations [Abstract]	'	'	'	'
Net revenues	$3,956,335	$3,198,534	$10,875,588	$11,086,190
Cost of revenues	1,436,195	756,693	3,476,570	3,309,148
Gross profit	2,520,140	2,441,841	7,399,018	7,777,042
Operating expenses	'	'	'	'
Selling, general and administrative	2,634,036	3,034,189	8,097,067	8,850,735
Research and development	103,166	101,460	405,009	311,899
Total operating expenses	2,737,202	3,135,649	8,502,076	9,162,634
Operating loss	-217,062	-693,808	-1,103,058	-1,385,592
Interest expense, net of interest income of $392, $618, $11,730, and $15,940 respectively	23,321	29,158	57,992	91,673
Net loss before income taxes	-240,383	-722,966	-1,161,050	-1,477,265
Income tax benefit (expense)	-764,000	292,000	-418,000	564,000
Net loss	($1,004,383)	($430,966)	($1,579,050)	($913,265)
Loss per share:	'	'	'	'
Basic and diluted	($0.12)	($0.05)	($0.19)	($0.11)
Weighted-average common shares outstanding:	'	'	'	'
Basic	8,114,252	8,114,252	8,114,252	8,114,252
Diluted	8,114,252	8,114,252	8,114,252	8,114,252

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Operations (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Operations [Abstract]	'	'	'	'
Interest income	$392	$618	$11,730	$15,940

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities	'	'
Net loss	($1,579,050)	($913,265)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation	409,651	344,695
Amortization of finite-life intangible assets	95,082	98,069
Amortization of debt issuance costs	13,078	8,691
Share-based compensation expense	73,821	132,179
Deferred income taxes	454,000	'
Loss on disposal of property and equipment	34,110	43,143
Changes in operating assets and liabilities:	'	'
Accounts receivable	2,544,116	1,652,815
Inventories	-1,171,221	250,971
Prepaid expenses and other assets	-37,930	-632,197
Accounts payable and accrued liabilities	184,333	5,086
Net cash provided by operating activities	1,019,990	990,187
Cash Flows From Investing Activities	'	'
Expenditures for property and equipment	-626,327	-707,140
Expenditures for finite-life intangible assets	-8,155	-35,642
Net cash used in investing activities	-634,482	-742,782
Cash Flows From Financing Activities	'	'
Net payments on revolving line of credit	'	-1,208,128
Principal payments on long-term debt including capital lease obligations	-81,348	-236,762
Payments of deferred financing fees	-35,296	'
Net cash used in financing activities	-116,644	-1,444,890
Net increase (decrease) in cash and cash equivalents	268,864	-1,197,485
Cash and cash equivalents	'	'
Beginning of period	503,564	1,702,435
End of period	$772,428	$504,950

Interim_Financial_Reporting

Interim Financial Reporting	9 Months Ended
	Mar. 31, 2014
Interim Financial Reporting [Abstract]	'
Interim Financial Reporting	'
	Note 1.	Interim Financial Reporting
	Basis of presentation: Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products which apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $585,000 and $552,000 for the nine months ended March 31, 2014 and 2013, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X, Rule 10-01. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2013.
	Principles of consolidation: The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Operating activities and net assets in Electromed Financial, LLC were insignificant as of and for the three and nine months ended March 31, 2014 and the year ended June 30, 2013.
	Liquidity: For the three and nine months ended March 31, 2014, the Company incurred a net loss of approximately $1,004,000 and $1,579,000, respectively. This was primarily as a result of a decrease in domestic home care revenues and the addition of a valuation allowance against the Company's deferred tax assets. Cash generated in operating activities was approximately $1,020,000, for the nine months ended March 31, 2014. The principal sources of liquidity in the future are expected to be cash flows from operations and availability on our line of credit. In order to operate profitably in the future, the Company must increase its revenue.
	The Company's ability to generate sufficient cash flows over the next year could be negatively impacted by the business challenges in reimbursement from third party payers. There continues to be downward pressure on pricing and added administrative procedures implemented by third party payers in the insurance claims process which has lengthened the approval process compared with the prior year. In fiscal 2013, one of the largest domestic third party payers decentralized its contracting process. As a result, the decentralization has required significantly more administrative efforts on the part of the Company to complete the necessary contracts to maintain our national coverage with that payer. Certain contracts were resolved during fiscal 2013, although the final completion of this process has extended into fiscal year 2014. The challenges the Company currently faces could result in future noncompliance with the covenants contained within the Company's credit facility. Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of the Company's indebtedness or preventing access to additional funds under the credit facility, or requiring prepayment of outstanding indebtedness under the credit facility. If the maturity of the indebtedness is accelerated, or the Company is unable to renew the line of credit, sufficient cash resources to satisfy the debt obligations may not be available and the Company may not be able to continue operations as planned. The indebtedness under the credit agreement is secured by a security interest in substantially all tangible and intangible assets of the Company. If the Company is unable to repay such indebtedness, the bank could foreclose on these assets.
	The Company was in violation of the tangible net worth covenant during the quarter ended March 31, 2014, and the bank has waived the event of default. On May 6, 2014, the Company entered into an amendment to the credit facility to reduce the requirement to maintain a minimum tangible net worth from $12,000,000 to $10,125,000. The Company believes it will be able to maintain compliance with the future covenants set forth in the amendment and negotiate an extension of the line of credit past its current expiration date of December 31, 2014, or obtain alternative financing.
	A summary of the Company's significant accounting policies follows:
	Use of estimates: Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.
	Net loss per common share: Net loss is presented on a per share basis for both basic and diluted common shares. Basic net loss per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net loss per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents of 609,900 and 624,900 were excluded from the calculation of diluted earnings per share for the three and nine months ended March 31, 2014 and 2013, respectively, as their impact was antidilutive.

Inventories

Inventories	9 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories	'
	Note 2.	Inventories
	The components of inventory were approximately as follows:
			March 31,			June 30,
			2014			2013
	Parts inventory		$	1,821,000		$	951,000
	Work in process			146,000			196,000
	Finished goods			614,000			263,000
	Less: Reserve for obsolescence			(30,000	)		(30,000	)
	Total		$	2,551,000		$	1,380,000

FiniteLife_Intangible_Assets

Finite-Life Intangible Assets	9 Months Ended
	Mar. 31, 2014
Finite-Life Intangible Assets [Abstract]	'
Finite-Life Intangible Assets	'
	Note 3.	Finite-Life Intangible Assets
	The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. Accumulated amortization was approximately $574,000 and $479,000 at March 31, 2014 and June 30, 2013, respectively.
	The activity and balances of finite-life intangible assets were approximately as follows:
			Nine Months			Year Ended
			Ended			30-Jun-13
			March 31,
			2014
	Balance, beginning		$	1,081,000		$	1,174,000
	Additions			8,000			37,000
	Amortization expense			(95,000	)		(130,000	)
	Balance, ending		$	994,000		$	1,081,000

Warranty_Liability

Warranty Liability	9 Months Ended
	Mar. 31, 2014
Warranty Liability [Abstract]	'
Warranty Liability	'
	Note 4.	Warranty Liability
	The Company provides a lifetime warranty on its products to the prescribed patient for sales within the United States and a three-year warranty for all institutional sales and sales to individuals outside the United States. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company's warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.
	Changes in the Company's warranty liability were approximately as follows:
			Nine Months			Year Ended
			Ended			30-Jun-13
			March 31,
			2014
	Beginning warranty reserve		$	680,000		$	610,000
	Accrual for products sold			192,000			232,000
	Expenditures and costs incurred for warranty claims			(132,000	)		(162,000	)
	Ending warranty reserve		$	740,000		$	680,000

Income_Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	Note 5.	Income Taxes
	On a quarterly basis, the Company estimates what its effective tax rate will be for the full fiscal year and records a quarterly income tax provision based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The effective tax rate for the nine months ended March 31, 2014 and 2013 was negative 36.0% and 38.2%, respectively. For the nine months ended March 31, 2014, the Company recorded an income tax expense of $418,000. This amount includes a current tax benefit of $36,000 and a discrete tax expense of $454,000 due primarily to the Company's recording of a full valuation allowance against all of its net US federal and state deferred tax assets at March 31, 2014. For the three months ended March 31, 2014, tax expense also included $346,000 of tax expense due to the reversal of the current tax benefit recorded during the first two quarters of the fiscal year.
	The Company assessed whether a valuation allowance should be established against its deferred tax assets based on consideration of all available evidence, using a "more likely than not" standard. In assessing the need for a valuation allowance, the Company considered both positive and negative evidence related to the likelihood of realization of deferred tax assets. In making such assessments, more weight was given to evidence that could be objectively verified. The Company's current and previous losses were given more weight than its future outlook. Under this approach, the recent cumulative losses and the loss recorded this quarter became a piece of significant negative evidence. This factor impaired the Company's ability to rely on future taxable income projections in determining whether a valuation allowance is appropriate. Future sources of taxable income considered in determining the amount of recorded valuation allowance included:
		•	Taxable income in prior carryback years, if carryback is permitted under the tax law;
		•	Future reversals of existing taxable temporary differences, excluding those related to indefinite-lived intangible assets;
		•	Tax planning strategies; and
		•	Future taxable income exclusive of reversing temporary differences and carryforwards.
	Based on the evaluation of these factors, in the quarter ended March 31, 2014, the Company determined that a full valuation allowance was appropriate. In future periods, the Company will continue to assess the likelihood that its deferred taxes will be realizable, and its valuation allowance will be adjusted accordingly, which could materially impact its financial position and results of operations.

Financing_Arrangements_And_Sub

Financing Arrangements And Subsequent Events	9 Months Ended
	Mar. 31, 2014
Financing Arrangements And Subsequent Events [Abstract]	'
Financing Arrangements And Subsequent Events	'
	Note 6.	Financing Arrangements and Subsequent Events
	On December 18, 2013, the Company entered into a new credit facility with Venture Bank, which replaced its facility with U.S. Bank. The new credit facility provides for a $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of March 31, 2014. Interest on the line of credit accrues at the prime rate plus 1.50%, with a floor of 4.50% (4.75% at March 31, 2014) and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.75% of eligible accounts receivable and the line of credit expires on December 18, 2014, if not renewed. The line of credit is secured by a security interest in substantially all of the tangible and intangible assets of the Company.
	As a part of the new credit facility, the Company also refinanced its outstanding U.S. Bank term loan which had an outstanding principal balance of approximately $1,341,000 and bore interest at 5.79%. It was repaid in full and replaced by a $1,300,000 term loan from Venture Bank that bears interest at 5.00%, with monthly payments of principal and interest of approximately $8,600 and a final payment of principal and interest of approximately $1,095,000 due on the maturity date of December 18, 2018. The term loan is secured by a mortgage on the Company's real property.
	The Company's new credit facility contains certain financial and nonfinancial covenants which include a minimum tangible net worth covenant of not less than $12,000,000 and restrictions on the Company's ability to incur certain additional indebtedness or pay dividends. As a result of paying off its outstanding loan and terminating its credit facility with U.S. Bank, the Company incurred approximately $3,000 in prepayment penalties.
	The Company was in violation of the tangible net worth covenants during the quarter ended March 31, 2014, and bank has waived the events of default. On May 6, 2014, the Company entered into an amendment to the credit facility to reduce the requirement to maintain a minimum tangible net worth from $12,000,000 to $10,125,000.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Mar. 31, 2014
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	Note 7.	Commitments and Contingencies
	The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition.

Related_Parties

Related Parties	9 Months Ended
	Mar. 31, 2014
Related Parties [Abstract]	'
Related Parties	'
	Note 8.	Related Parties
	The Company uses a parts supplier whose founder and president is a director of the Company. For the nine months ended March 31, 2014 and 2013, the Company made payments to the supplier of approximately $163,000 and $288,000, respectively.

Interim_Financial_Reporting_Po

Interim Financial Reporting (Policy)	9 Months Ended
	Mar. 31, 2014
Interim Financial Reporting [Abstract]	'
Nature Of Business	'
	Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products which apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $585,000 and $552,000 for the nine months ended March 31, 2014 and 2013, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.
Basis Of Presentation	'
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X, Rule 10-01. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended June 30, 2013.
Principles Of Consolidation	'
	Principles of consolidation: The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Operating activities and net assets in Electromed Financial, LLC were insignificant as of and for the three and nine months ended March 31, 2014 and the year ended June 30, 2013.
Liquidity	'
	Liquidity: For the three and nine months ended March 31, 2014, the Company incurred a net loss of approximately $1,004,000 and $1,579,000, respectively. This was primarily as a result of a decrease in domestic home care revenues and the addition of a valuation allowance against the Company's deferred tax assets. Cash generated in operating activities was approximately $1,020,000, for the nine months ended March 31, 2014. The principal sources of liquidity in the future are expected to be cash flows from operations and availability on our line of credit. In order to operate profitably in the future, the Company must increase its revenue.
	The Company's ability to generate sufficient cash flows over the next year could be negatively impacted by the business challenges in reimbursement from third party payers. There continues to be downward pressure on pricing and added administrative procedures implemented by third party payers in the insurance claims process which has lengthened the approval process compared with the prior year. In fiscal 2013, one of the largest domestic third party payers decentralized its contracting process. As a result, the decentralization has required significantly more administrative efforts on the part of the Company to complete the necessary contracts to maintain our national coverage with that payer. Certain contracts were resolved during fiscal 2013, although the final completion of this process has extended into fiscal year 2014. The challenges the Company currently faces could result in future noncompliance with the covenants contained within the Company's credit facility. Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of the Company's indebtedness or preventing access to additional funds under the credit facility, or requiring prepayment of outstanding indebtedness under the credit facility. If the maturity of the indebtedness is accelerated, or the Company is unable to renew the line of credit, sufficient cash resources to satisfy the debt obligations may not be available and the Company may not be able to continue operations as planned. The indebtedness under the credit agreement is secured by a security interest in substantially all tangible and intangible assets of the Company. If the Company is unable to repay such indebtedness, the bank could foreclose on these assets.
	The Company was in violation of the tangible net worth covenant during the quarter ended March 31, 2014, and the bank has waived the event of default. On May 6, 2014, the Company entered into an amendment to the credit facility to reduce the requirement to maintain a minimum tangible net worth from $12,000,000 to $10,125,000. The Company believes it will be able to maintain compliance with the future covenants set forth in the amendment and negotiate an extension of the line of credit past its current expiration date of December 31, 2014, or obtain alternative financing.
Use Of Estimates	'
	Use of estimates: Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve.
Net Loss Per Common Share	'
	Net loss per common share: Net loss is presented on a per share basis for both basic and diluted common shares. Basic net loss per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net loss per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents of 609,900 and 624,900 were excluded from the calculation of diluted earnings per share for the three and nine months ended March 31, 2014 and 2013, respectively, as their impact was antidilutive.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Schedule Of Components Of Inventory	'
		March 31,			June 30,
		2014			2013
	Parts inventory	$	1,821,000		$	951,000
	Work in process		146,000			196,000
	Finished goods		614,000			263,000
	Less: Reserve for obsolescence		(30,000	)		(30,000	)
	Total	$	2,551,000		$	1,380,000

FiniteLife_Intangible_Assets_T

Finite-Life Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2014
Finite-Life Intangible Assets [Abstract]	'
Schedule Of Finite-Life Intangible Assets	'
		Nine Months			Year Ended
		Ended			30-Jun-13
		March 31,
		2014
	Balance, beginning	$	1,081,000		$	1,174,000
	Additions		8,000			37,000
	Amortization expense		(95,000	)		(130,000	)
	Balance, ending	$	994,000		$	1,081,000

Warranty_Liability_Tables

Warranty Liability (Tables)	9 Months Ended
	Mar. 31, 2014
Warranty Liability [Abstract]	'
Schedule Of Warranty Liability	'
		Nine Months			Year Ended
		Ended			30-Jun-13
		March 31,
		2014
	Beginning warranty reserve	$	680,000		$	610,000
	Accrual for products sold		192,000			232,000
	Expenditures and costs incurred for warranty claims		(132,000	)		(162,000	)
	Ending warranty reserve	$	740,000		$	680,000

Interim_Financial_Reporting_De

Interim Financial Reporting (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	6-May-14	5-May-14
					International [Member]	International [Member]	Venture Bank [Member]	Venture Bank [Member]	Venture Bank [Member]
								Subsequent Event [Member]	Subsequent Event [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'	'	'	'	'
Sales	$3,956,335	$3,198,534	$10,875,588	$11,086,190	$585,000	$552,000	'	'	'
Net income (loss)	-1,004,383	-430,966	-1,579,050	-913,265	'	'	'	'	'
Cash provided by (used in) operating activities	'	'	1,019,990	990,187	'	'	'	'	'
Minimum tangible net worth to be maintained	'	'	'	'	'	'	$12,000,000	$10,125,000	$12,000,000
Common stock equivalents excluded from calculation of diluted earnings per share	609,900	624,900	609,900	624,900	'	'	'	'	'

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013
Inventories [Abstract]	'	'
Parts inventory	$1,821,000	$951,000
Work in process	146,000	196,000
Finished goods	614,000	263,000
Less: Reserve for obsolescence	-30,000	-30,000
Total	$2,550,815	$1,379,594

FiniteLife_Intangible_Assets_N

Finite-Life Intangible Assets (Narrative) (Details) (USD $)	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2014	Mar. 31, 2014
			Patents [Member]	Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Estimated useful life	'	'	'15 years	'12 years
Accumulated amortization	$574,000	$479,000	'	'

FiniteLife_Intangible_Assets_S

Finite-Life Intangible Assets (Schedule Of Finite-Life Intangible Assets) (Details) (USD $)	9 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Jun. 30, 2013
Finite-Life Intangible Assets [Abstract]	'	'	'
Balance, beginning	$1,080,734	$1,174,000	$1,174,000
Additions	8,000	'	37,000
Amortization expense	-95,082	-98,069	-130,000
Balance, ending	$993,807	'	$1,080,734

Warranty_Liability_Narrative_D

Warranty Liability (Narrative) (Details) (Outside United States [Member])	9 Months Ended
	Mar. 31, 2014
Outside United States [Member]	'
Warranty Liability [Line Items]	'
Warranty term	'3 years

Warranty_Liability_Schedule_Of

Warranty Liability (Schedule Of Warranty Liability) (Details) (USD $)	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Jun. 30, 2013
Warranty Liability [Abstract]	'	'
Beginning warranty reserve	$680,000	$610,000
Accrual for products sold	192,000	232,000
Expenditures and costs incurred for warranty claims	-132,000	-162,000
Ending warranty reserve	$740,000	$680,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Income Taxes [Abstract]	'	'	'	'
Effective tax rate	'	'	-36.00%	38.20%
Income tax expense	$764,000	($292,000)	$418,000	($564,000)
Current tax expense (benefit)	'	'	-36,000	'
Discrete tax expense	'	'	454,000	'
Tax expense due to reversal of current tax benefit recorded during first two quarters of the fiscal year	$346,000	'	'	'

Financing_Arrangements_And_Sub1

Financing Arrangements And Subsequent Events (Details) (USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Dec. 18, 2013	6-May-14	5-May-14
	Venture Bank [Member]	U.S. Bank [Member]	U.S. Bank [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Venture Bank [Member]	Venture Bank [Member]
Line of Credit Facility [Line Items]	'	'	'	'	'
Maximum borrowing capacity	$2,500,000	'	'	'	'
Outstanding principal balance	0	'	1,341,000	'	'
Amount added to prime rate for interest rate	1.50%	'	'	'	'
Interest rate, floor	4.50%	'	'	'	'
Effective interest rate including prime rate	4.75%	'	'	'	'
Borrowing restriction, revolving line of credit	2,500,000	'	'	'	'
Borrowing restriction, percent of eligible accounts receivable	57.75%	'	'	'	'
Credit facility expiration date	18-Dec-14	'	'	'	'
Interest rate	'	'	5.79%	'	'
Term loan	1,300,000	'	'	'	'
Term loan, interest rate	5.00%	'	'	'	'
Monthly payments of principal and interest	8,600	'	'	'	'
Final payment of principal and interest	1,095,000	'	'	'	'
Term loan maturity date	18-Dec-18	'	'	'	'
Minimum tangible net worth to be maintained	12,000,000	'	'	10,125,000	12,000,000
Prepayment penalties incurred	'	$3,000	'	'	'

Related_Parties_Details

Related Parties (Details) (USD $)	9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Related Party Transaction [Line Items]	'	'
Payments to related party parts supplier	$163,000	$288,000
Member Of Electromed's Board Of Directors [Member]	'	'
Related Party Transaction [Line Items]	'	'
Number of related parties	1	'